Who are Magnesium aluminum hydroxide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tums, Milk of Magnesia, Sodium Bicarbonate and Sodium chloride, Drug either PPIS or H2RA and prokinetics, Sodium Bicarbonate Powder and ondansetron, NaHCO3.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/magnesium-aluminum-hydroxide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Magnesium aluminum hydroxide — Competitive Intelligence Brief

Magnesium aluminum hydroxide (Magnesium aluminum hydroxide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antacid. Area: Gastroenterology.

marketed Antacid Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Magnesium aluminum hydroxide (Magnesium aluminum hydroxide) — Isfahan University of Medical Sciences. Magnesium aluminum hydroxide is an antacid that neutralizes gastric acid by reacting with hydrochloric acid in the stomach to form water and neutral salts.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Magnesium aluminum hydroxide TARGET	Magnesium aluminum hydroxide	Isfahan University of Medical Sciences	marketed	Antacid
Tums	calcium carbonate	Generic (multiple manufacturers)	marketed	Antacid, Calcium supplement	Gastric acid (direct neutralization)	1930-01-01
Milk of Magnesia	magnesium hydroxide	Generic (multiple manufacturers)	marketed	Osmotic laxative, Antacid	Gastric acid (direct neutralization) + osmotic effect in intestine	1880-01-01
Sodium Bicarbonate and Sodium chloride	Sodium Bicarbonate and Sodium chloride	University Hospital, Clermont-Ferrand	marketed	Electrolyte and antacid combination
Drug either PPIS or H2RA and prokinetics	Drug either PPIS or H2RA and prokinetics	King Saud University	marketed	Combination antacid and prokinetic agent	H+/K+-ATPase (PPIs) or H2 receptor (H2RAs); dopamine antagonist or other prokinetic target
Sodium Bicarbonate Powder and ondansetron	Sodium Bicarbonate Powder and ondansetron	Aya Sabry Mohamed Mohamed	marketed	Antacid and antiemetic combination	5-HT3 receptor (ondansetron); non-specific acid neutralization (sodium bicarbonate)
NaHCO3	NaHCO3	Karadeniz Technical University	marketed	Antacid / Alkalizing agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antacid class)

Amorphical Ltd. · 1 drug in this class
Bosnalijek D.D · 1 drug in this class
HALEON · 1 drug in this class
Isfahan University of Medical Sciences · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
POZEN · 1 drug in this class
Western Galilee Hospital-Nahariya · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Magnesium aluminum hydroxide — Competitive Intelligence Brief. https://druglandscape.com/ci/magnesium-aluminum-hydroxide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab